TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02555943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Description: Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir/Sofosbuvir
Description: Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Daclatasvir
Description: TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir and Daclatasvir
Description: TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
Description: VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
Description: VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
Study: NCT00408694

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT03393767

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Intravitreal injection
Study: NCT03220906

Intervention type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure will be measured in both upper and lower extremities.
Study: NCT01417494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
Study: NCT02361632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee with or without milk
Description: Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee with or without milk
Description: Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee with or without milk
Description: Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
Study: NCT01305577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT03059680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High potassium diet
Description: An increase in consumption of high potassium fruits and vegetables
Study: NCT04252976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ethical Living
Description: Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ethical Living
Description: Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Exercises
Description: Ujjaii breathing and simple yoga asanas

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Exercises
Description: Ujjaii breathing and simple yoga asanas

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Meditation with mantras

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Meditation with mantras

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Meditation with mantras

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Meditation with mantras
Study: NCT02745015

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-surgical periodontal treatment
Description: full-mouth scaling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: full-mouth scaling and root planing
Study: NCT00796978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
Study: NCT02672293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phoslax
Description: Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
Study: NCT03795272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 2:1 randomization to receive rucaparib/placebo twice daily for 24 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00420043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Study: NCT02176252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03334786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX-787-ODT
Description: Oral Disintegrating Tablet
Study: NCT01030926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Study: NCT02565667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KOL
Description: KOL staple was used for rectal anastomosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional staple
Description: traditional staple was used for rectal anastomosis
Study: NCT03144934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo of GX-I7 described above.
Study: NCT01034670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual axis endoscopic microscope
Description: This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wide field fluorescence system
Description: This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellVizio
Description: Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescent Peptide
Description: microdosing; Topical through the endoscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein
Description: 100 mcg topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: 100 mcg topical
Study: NCT01627288

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost radiation
Description: Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost radiation
Description: Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost radiation
Description: Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost radiation
Description: Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
Study: NCT00711477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/bupropion SR 360 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scan
Description: fMRI to assess the effects of the drug/placebo on areas of the brain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fMRI scan
Description: fMRI to assess the effects of the drug/placebo on areas of the brain
Study: NCT03849118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-girentuximab
Description: Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
Study: NCT04765228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib
Study: NCT01456897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: orally administered once daily
Study: NCT00493051

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAM501
Description: Ad5PDGF-B formulated in a collagen gel

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAM501
Description: Ad5PDGF-B formulated in a collagen gel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Collagen gel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Collagen gel

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: moist dressing changes daily
Study: NCT02657603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injected through the new Catheter (LAX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injected through the new Catheter (SAX)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAX insertion of catheter
Description: ultra sound guided cather insertion in the long axis (LAX) of the adductor canal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAX insertion of catheter
Description: ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
Study: NCT02377739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation
Description: patients will undergo a nocturnal non-invasive ventilation
Study: NCT01339520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scorecard
Description: Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard of care for diabetes subjects
Study: NCT04535453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
Study: NCT02980913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo eye drops and Thealoz Duo gel
Description: Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo eye drops and Thealoz Duo gel
Description: Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo gel
Description: Thealoz Duo gel during the day and at night for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo gel
Description: Thealoz Duo gel during the day and at night for 7 days
Study: NCT01911962

Intervention type: PROCEDURE
Intervention: transvaginal laparoscopic surgery
Study: NCT04279613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0361-0041
Description: Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02929407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 204205
Description: In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
Study: NCT03418961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02398591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 53718678
Description: JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
Study: NCT03418961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study: NCT00982059

Intervention type: OTHER
Intervention: Colonoscopic examination
Description: All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
Study: NCT00850421

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type A
Description: 100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
Study: NCT00280748

Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed disodium
Description: 500 mg/m2 once every 21 days up to 126 days

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
Study: NCT04978103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
Study: NCT03794830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manipulation group (MG)
Description: Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrotheraphy group (EG)
Description: Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)